Summary

Samenvatting Neurogenetics (2078FBDBMW)

5 purchases

Course
Neurogenetics (2078FBDBMW)

Institution
Universiteit Antwerpen (UA)

Samenvatting Neurogenetics - Intro to neurogenetics - Genetic mechanisms - Repeat expansion disorders - Genetic disease modifiers - Therapeutic strategies - Disease focus: genetics of neurocutaneous disorders

[Show more]

Preview 4 out of 122 pages

View example

Uploaded on February 1, 2023
Number of pages 122
Written in 2021/2022
Type Summary

neurogenetics

Institution
Universiteit Antwerpen (UA)
Education
Biomedische Wetenschappen
Course
Neurogenetics (2078FBDBMW)

lizaburdz

Member since 7 year 48 documents sold

$7.56

Add to cart

Add to wishlist

100% satisfaction guarantee
Immediately available after payment
Both online and in PDF
No strings attached

Neurogenetics
Exam
Mondeling met schriftelijke voorbereiding
Written exam with oral explanation
- 3 open questions
- Questions where you need discuss/apply the theory
- Links some things together; fill in words,…

Contents
Introduction to Neurogenetics........................................................................................................... 7
Neurological disorders are a major health problem ....................................................................... 7
Classification of neurological disorders .......................................................................................... 7
Overall ....................................................................................................................................... 7
Movement disorders ................................................................................................................. 8
Dementias ................................................................................................................................. 8
Disease of white matter ............................................................................................................. 8
Neuromuscular disorders........................................................................................................... 9
Paroxysmal disorders ................................................................................................................. 9
Neurodevelopmental disorders ................................................................................................. 9
Neurocutaneous disorders (phakomatoses) ............................................................................. 10
Cerebrovascular diseases ......................................................................................................... 10
Major adult psychiatric disorders ............................................................................................. 10
Unifying themes in neurological disorders ................................................................................... 10
Factors suggesting a neurogenetic disorder ................................................................................. 10
Inheritance patterns in neurological disorders ............................................................................. 11
Autosomal dominant ............................................................................................................... 11
Autosomal recessive ................................................................................................................ 11
X-linked dominant ................................................................................................................... 11
X-linked recessive .................................................................................................................... 11
Y-linked inheritance ................................................................................................................. 12
Examples ................................................................................................................................. 12
Most patients/families affected by neurological disorders do not have clear inheritance pattern
................................................................................................................................................ 13
From monogenic disorders to complex diseases ...................................................................... 13
Gene discovery ............................................................................................................................ 14

1

, Impact of gene discovery ......................................................................................................... 14
Classical linkage approaches in families – linkage analysis ........................................................ 14
Population genetics ................................................................................................................. 15
Example – Amyotrophic lateral sclerosis...................................................................................... 19
Most neurological diseases are genetically heterogeneous with multiple modes of inheritance –
eg ALS ...................................................................................................................................... 19
Familial ALS genes.................................................................................................................... 19
Oligogenic basis of ALS............................................................................................................. 20
Gene x environment interaction in ALS .................................................................................... 20
ALS risk genes identified through GWAS .................................................................................. 21
Polygenic risk score suggest genetic overlap between ALS and schizophrenia ........................ 21
Exome sequencing study in ALS identified TBK1 mutations ...................................................... 21
Types of disease-causing genetic variation................................................................................... 21
Classification of mutations by their effects on the DNA molecule ............................................. 21
Mutations affecting the coding sequence ................................................................................ 22
Mutations affecting the non-coding regions............................................................................. 23
Example – microtubule associated protein tau gene (MAPT) .................................................... 24
Key concepts ............................................................................................................................... 25
Genetic mechanisms ....................................................................................................................... 26
Genetic mechanisms in neurological disorders ............................................................................ 26
Loss-of-function mutations .......................................................................................................... 26
Gain-of-function mutations ......................................................................................................... 26
Examples ..................................................................................................................................... 27
Example 1: Spinal muscular atrophy (SMA) .............................................................................. 27
Example 2: CADASIL ................................................................................................................. 28
Example 3: Alexander disease .................................................................................................. 31
Example 4: NPTX1 in cerebellar ataxia ..................................................................................... 33
Example 5: TBK1 mutations in ALS ........................................................................................... 35
Mechanisms of mutations affecting non-coding regions .............................................................. 37
Introduction ............................................................................................................................ 37
ALS and FTLD-TDP share common pathology – TDP43 pathology ............................................. 37
Transcriptomic analysis of TDP43-negative neurons................................................................. 37
Identification of cryptic exons in neurons without TDP-43....................................................... 38
TDP-43 loss induces cryptic splicing of UNC13A in vitro ............................................................ 38
Most significant UNC13A risk variant is located in non- coding region located in cryptic exon . 39
Role of epigenetics in neurological disorders ............................................................................... 39

2

, Epigenetics .............................................................................................................................. 39
Example - Facioscapulohumeral muscular dystrophy (FSHD ..................................................... 40
Mosaic mutations in neurological disorders ................................................................................. 42
De novo and mosaic mutations ................................................................................................ 42
Facts about mosaic mutations in brain ..................................................................................... 42
Example 1: possible somatic mutations in ALS family ............................................................... 43
Example 2: focal cortical dysplasia ........................................................................................... 43
Example question .................................................................................................................... 43
Example 3: ‘second hit’ somatic mutations produce mosaicsm ................................................ 44
Role of mitochondrial genome in neurological diseases ............................................................... 44
General.................................................................................................................................... 44
Mitochondrial mutations ......................................................................................................... 44
Mitochondrial genome analysis ............................................................................................... 45
Example questions....................................................................................................................... 45
Key Concepts ............................................................................................................................... 45
Repeat expansion disorders............................................................................................................. 46
What are tandem repeat expansions ........................................................................................... 46
General.................................................................................................................................... 46
Tandem repeat unit sizes ......................................................................................................... 46
Many tandem repeats are unstable ......................................................................................... 46
Some tandem repeats are pathogenic ..................................................................................... 47
Anticipation ............................................................................................................................. 47
Timelines of discoveries ........................................................................................................... 47
Lab methods for tandem repeats ................................................................................................. 48
Southern blotting..................................................................................................................... 48
PCR .......................................................................................................................................... 48
Repeat-primer PCR .................................................................................................................. 49
Short-read sequencing ............................................................................................................. 49
Long-read sequencing .............................................................................................................. 50
Intermezzo on human genetic variation and sequencing methods ........................................... 50
RNA-fish .................................................................................................................................. 50
Repeats and neurological diseases............................................................................................... 51
Location of pathogenic expansions matters ............................................................................. 51
Huntington’s disease ............................................................................................................... 52
Spinocerebellar ataxia ............................................................................................................. 52
Familiar adult myoclonic epilepsy (FAME) ................................................................................ 55

3

, AD risk-associated VNTR expansion in ABCA7 .......................................................................... 56
Regulatory effects.................................................................................................................... 56
key concepts................................................................................................................................ 57
Genetic disease modifiers................................................................................................................ 58
Definitions ................................................................................................................................... 58
Intro ........................................................................................................................................ 58
Illustration of the power of (genetic) modifiers ........................................................................ 58
Definitions of genetic modifier ................................................................................................. 58
Genetic modifier vs oligogenic disease ..................................................................................... 59
Approaches to identify genetic disease modifiers ........................................................................ 59
Intro ........................................................................................................................................ 59
Considerations......................................................................................................................... 59
Through human/population studies ............................................................................................. 59
Example 1: Spinal muscular atrophy......................................................................................... 59
Example 2: Huntington’s disease (HD)...................................................................................... 61
Example 3: Frontotemporal dementia (FTD) ............................................................................ 65
Example 4: Progressive supranuclear palsy (PSP) ..................................................................... 66
Through model organism genetics ............................................................................................... 67
Discussion on importance of model validity ............................................................................. 67
Multifactorial validity in animal models ................................................................................... 68
Model organisms ..................................................................................................................... 68
Choice of model system is a balance between physiological relevance against cost and
throughput .............................................................................................................................. 69
Example 1: Peripheral Neuropathy (GAL4/UAS system Drosophila) .......................................... 69
Example 2: Parkinson’s disease (Drosophila Genetic Reference Panel) ..................................... 70
Example 3: TDP-43 and ALS (Yeast, Drosophila, human) – genetic modifier screen in model
systems with relevance for human disease .............................................................................. 71
Example 4: Duchenne Muscular Dystrophy (dog) ..................................................................... 74
Example 5: Epilepsy (mice)....................................................................................................... 75
Through functional assays ........................................................................................................... 76
Functional genomics ................................................................................................................ 76
Overview methods CRISPR/cas9 .............................................................................................. 77
Example 1: Toxicity dipeptide repeat proteins in C9orf72 disease ............................................ 78
Key concepts ............................................................................................................................... 79
Therapeutic strategies ..................................................................................................................... 80
Introduction to treating genetic neurological diseases ................................................................. 80

4

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller lizaburdz. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $7.56. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

68175 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 15 years now

Start selling

Summary

Samenvatting Neurogenetics (2078FBDBMW)

Document information

Subjects

Written for

Seller

Reviews received

Content preview